董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jon Hindar Chairman of the Board 64 未披露 未持股 2021-03-15
Johan Lund Director 63 未披露 未持股 2021-03-15
Nicolas Roelofs Director 63 未披露 未持股 2021-03-15
Gustavo Salem Director 57 未披露 未持股 2021-03-15
Tommi Unkuri Director 40 未披露 未持股 2021-03-15
Jon Heimer Chief Executive Officer and Director 53 未披露 未持股 2021-03-15
Solange Glaize Director 56 未披露 未持股 2021-03-15
Tina S. Nova Director 67 未披露 未持股 2021-03-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Jon Heimer Chief Executive Officer and Director 53 未披露 未持股 2021-03-15
Oskar Hjelm Chief Financial Officer 36 未披露 未持股 2021-03-15
Rickard El Tarzi Chief Strategy Officer 35 未披露 未持股 2021-03-15
Ida Grundberg Chief Scientific Officer 38 未披露 未持股 2021-03-15
Carl Raimond Chief Commercial Officer 50 未披露 未持股 2021-03-15
Fredrik Netzel Chief Operating Officer 52 未披露 未持股 2021-03-15
Linda Ramirez Eaves General Counsel 49 未披露 未持股 2021-03-15

董事简历

中英对照 |  中文 |  英文
Jon Hindar

Jon Hindar自2021年1月起担任我们的董事会主席。Hindar先生自2017年1月起担任Summa Equity AB的负责人。2015年至2017年,Hindar先生担任Argentum FondsInvesteringer AS,HAV Line AS和LGJ Invest AS的董事会主席。从2012年3月至2016年6月,Hindar先生担任Cermaq Group AS的首席执行官。Hindar先生自2020年6月起担任Arendals Fossekompani ASA的董事会主席,还担任多家私人控股公司的董事会成员,包括Milarex AS,Klaveness Marine Holding AS,LGJ Invest AS,Hytest Group和Argentum FondsInvesteringer AS。Hindar先生在挪威科技大学(Norwegian University of Science and Technology)获得化学科学与工程硕士学位,并在洛桑IMD完成了高管发展课程。


Jon Hindar has served as chairman of our Board of Directors since January 2021. Mr. Hindar has served as a Principal of Summa Equity AB since January 2017. From 2015 until 2017 Mr. Hindar served as chairman of the board of directors of Argentum Fondsinvesteringer AS, Hav Line AS and LGJ Invest AS. From March 2012 until June 2016 Mr. Hindar served as Chief Executive Officer of Cermaq Group AS. Mr. Hindar has served as chairman of the board of directors of Arendals Fossekompani ASA since June 2020 and also serves on the boards of multiple privately-held companies, including Milarex AS, Klaveness Marine Holding AS, LGJ Invest AS, HyTest Group, and Argentum Fondsinvesteringer AS. Mr. Hindar received his Master of Science and Engineering in chemistry from the Norwegian University of Science and Technology, and completed the Programme for Executive Development at IMD, Lausanne.
Jon Hindar自2021年1月起担任我们的董事会主席。Hindar先生自2017年1月起担任Summa Equity AB的负责人。2015年至2017年,Hindar先生担任Argentum FondsInvesteringer AS,HAV Line AS和LGJ Invest AS的董事会主席。从2012年3月至2016年6月,Hindar先生担任Cermaq Group AS的首席执行官。Hindar先生自2020年6月起担任Arendals Fossekompani ASA的董事会主席,还担任多家私人控股公司的董事会成员,包括Milarex AS,Klaveness Marine Holding AS,LGJ Invest AS,Hytest Group和Argentum FondsInvesteringer AS。Hindar先生在挪威科技大学(Norwegian University of Science and Technology)获得化学科学与工程硕士学位,并在洛桑IMD完成了高管发展课程。
Jon Hindar has served as chairman of our Board of Directors since January 2021. Mr. Hindar has served as a Principal of Summa Equity AB since January 2017. From 2015 until 2017 Mr. Hindar served as chairman of the board of directors of Argentum Fondsinvesteringer AS, Hav Line AS and LGJ Invest AS. From March 2012 until June 2016 Mr. Hindar served as Chief Executive Officer of Cermaq Group AS. Mr. Hindar has served as chairman of the board of directors of Arendals Fossekompani ASA since June 2020 and also serves on the boards of multiple privately-held companies, including Milarex AS, Klaveness Marine Holding AS, LGJ Invest AS, HyTest Group, and Argentum Fondsinvesteringer AS. Mr. Hindar received his Master of Science and Engineering in chemistry from the Norwegian University of Science and Technology, and completed the Programme for Executive Development at IMD, Lausanne.
Johan Lund

Johan Lund自2020年12月起担任我们的董事会成员。自2018年8月起担任Kynexis Medicine Development AB的联合创始人兼首席执行官。自2018年6月起,隆德博士还担任他创立的MBS Pharma的顾问。在此之前,隆德博士于2016年3月至2017年5月担任新基医药公司卓越免疫和炎症治疗中心Vice President兼负责人。2015年4月至2016年3月,Lund博士担任J.Lund and Associates,LLC的管理合伙人,2015年5月至2016年3月,Lund博士担任卡罗林斯卡学院的高级顾问,作为欧洲创新和技术研究所经济转型健康联合会的一部分,就创新和创业提供咨询意见。从2012年8月至2015年3月,隆德博士担任辉瑞公司免疫科学研究部高级副总裁兼首席科学官Lund博士自2018年6月起担任Aqilion AB的董事会主席,并是几家私人控股公司的董事会成员,包括Genagon Therapeutics AB和Neogap AB(前身为TCER AB)。隆德医生拿到了他的医学学位。Karolinska Institutet医学科学博士学位和他的博士学位。Lund博士还持有哥本哈根斯堪的纳维亚国际管理学院(Scandinavian International Management Institute)的管理医疗产品创新文凭。


Johan Lund has served as a member of our Board of Directors since December 2020. He has served as the co-founder and Chief Executive Officer of KyNexis Medicine Development AB since August 2018. Since June 2018 Dr. Lund has also served as a consultant for MBS Pharma, which he founded. Prior to that, from March 2016 until May 2017 Dr. Lund served as Vice President and Head of the Immunology and Inflammation Therapeutic Center of Excellence of Celgene Corporation. From April 2015 until March 2016 Dr. Lund was Managing Partner at J. Lund and Associates, LLC, and from May 2015 until March 2016 Dr. Lund was a Senior Advisor for the Karolinska Institutet, advising on innovation and business creation as part of the European Institute for Innovation and Technology EIT Health Consortium. From August 2012 until March 2015 Dr. Lund served as Senior Vice President and Chief Scientific Officer of the Immunoscience Research Unit of Pfizer Inc. Dr. Lund has served as chairman of the board of directors for Aqilion AB since June 2018 and is a member of the board of directors of several privately-held companies, including Genagon Therapeutics AB and NEOGAP AB (formerly Tcer AB). Dr. Lund received his Med.Kand. degree and his Doctor of Medical Science degree from Karolinska Institutet. Dr. Lund also holds a diploma in Managing Medical Product Innovation from the Scandinavian International Management Institute in Copenhagen.
Johan Lund自2020年12月起担任我们的董事会成员。自2018年8月起担任Kynexis Medicine Development AB的联合创始人兼首席执行官。自2018年6月起,隆德博士还担任他创立的MBS Pharma的顾问。在此之前,隆德博士于2016年3月至2017年5月担任新基医药公司卓越免疫和炎症治疗中心Vice President兼负责人。2015年4月至2016年3月,Lund博士担任J.Lund and Associates,LLC的管理合伙人,2015年5月至2016年3月,Lund博士担任卡罗林斯卡学院的高级顾问,作为欧洲创新和技术研究所经济转型健康联合会的一部分,就创新和创业提供咨询意见。从2012年8月至2015年3月,隆德博士担任辉瑞公司免疫科学研究部高级副总裁兼首席科学官Lund博士自2018年6月起担任Aqilion AB的董事会主席,并是几家私人控股公司的董事会成员,包括Genagon Therapeutics AB和Neogap AB(前身为TCER AB)。隆德医生拿到了他的医学学位。Karolinska Institutet医学科学博士学位和他的博士学位。Lund博士还持有哥本哈根斯堪的纳维亚国际管理学院(Scandinavian International Management Institute)的管理医疗产品创新文凭。
Johan Lund has served as a member of our Board of Directors since December 2020. He has served as the co-founder and Chief Executive Officer of KyNexis Medicine Development AB since August 2018. Since June 2018 Dr. Lund has also served as a consultant for MBS Pharma, which he founded. Prior to that, from March 2016 until May 2017 Dr. Lund served as Vice President and Head of the Immunology and Inflammation Therapeutic Center of Excellence of Celgene Corporation. From April 2015 until March 2016 Dr. Lund was Managing Partner at J. Lund and Associates, LLC, and from May 2015 until March 2016 Dr. Lund was a Senior Advisor for the Karolinska Institutet, advising on innovation and business creation as part of the European Institute for Innovation and Technology EIT Health Consortium. From August 2012 until March 2015 Dr. Lund served as Senior Vice President and Chief Scientific Officer of the Immunoscience Research Unit of Pfizer Inc. Dr. Lund has served as chairman of the board of directors for Aqilion AB since June 2018 and is a member of the board of directors of several privately-held companies, including Genagon Therapeutics AB and NEOGAP AB (formerly Tcer AB). Dr. Lund received his Med.Kand. degree and his Doctor of Medical Science degree from Karolinska Institutet. Dr. Lund also holds a diploma in Managing Medical Product Innovation from the Scandinavian International Management Institute in Copenhagen.
Nicolas Roelofs

Nicolas Roelofs自2020年12月以来一直担任我们的董事会成员。Roelofs博士自2019年7月起担任Summa Equity AB的负责人。Roelofs博士自2014年以来还担任Nordic Capital的工业顾问。Roelofs博士担任多家私人控股公司的董事会主席,包括Sengenics Corporation Pte Ltd.,One Biomed Pte Ltd.,Scalebio Ltd.和Boreal Genomics Inc.。Roelofs博士还担任多家私人控股公司的董事会成员,包括Hytest Ltd.,The Binding Site Group Ltd.,Insilixa,Inc.和LGC Group。他也是908DevicesInc.的顾问委员会成员Roelofs博士此前曾担任安捷伦科技公司(Agilent Technologies)的生命科学集团总裁,Bio-Rad Inc.生命科学部门的集团运营官,以及Stratagene Inc.的首席运营官。Roelofs博士在辛普森学院(Simpson College)获得化学、生物学和德语理学学士学位,在爱荷华州立大学(Iowa State University)获得有机化学理学硕士学位,在内华达大学里诺分校(University of Nevada,Reno)获得有机化学博士学位。


Nicolas Roelofs has served as a member of our Board of Directors since December 2020. Dr. Roelofs has served as a Principal of Summa Equity AB since July 2019. Dr. Roelofs has also served as Industrial Advisor of Nordic Capital since 2014. Dr. Roelofs serves as chairman of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., One BioMed Pte Ltd., ScaleBio Ltd., and Boreal Genomics Inc. Dr. Roelofs also serves as a member of the board of directors of multiple privately-held companies, including HyTest Ltd., The Binding Site Group Ltd., InSilixa, Inc., and LGC Group. He also serves as an advisory board member of 908 Devices Inc. Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc., and Chief Operating Officer of Stratagene Inc. Dr. Roelofs received his Bachelor of Science in chemistry, biology, and German from Simpson College, his Master of Science in organic chemistry from Iowa State University, and his doctorate in organic chemistry from University of Nevada, Reno.
Nicolas Roelofs自2020年12月以来一直担任我们的董事会成员。Roelofs博士自2019年7月起担任Summa Equity AB的负责人。Roelofs博士自2014年以来还担任Nordic Capital的工业顾问。Roelofs博士担任多家私人控股公司的董事会主席,包括Sengenics Corporation Pte Ltd.,One Biomed Pte Ltd.,Scalebio Ltd.和Boreal Genomics Inc.。Roelofs博士还担任多家私人控股公司的董事会成员,包括Hytest Ltd.,The Binding Site Group Ltd.,Insilixa,Inc.和LGC Group。他也是908DevicesInc.的顾问委员会成员Roelofs博士此前曾担任安捷伦科技公司(Agilent Technologies)的生命科学集团总裁,Bio-Rad Inc.生命科学部门的集团运营官,以及Stratagene Inc.的首席运营官。Roelofs博士在辛普森学院(Simpson College)获得化学、生物学和德语理学学士学位,在爱荷华州立大学(Iowa State University)获得有机化学理学硕士学位,在内华达大学里诺分校(University of Nevada,Reno)获得有机化学博士学位。
Nicolas Roelofs has served as a member of our Board of Directors since December 2020. Dr. Roelofs has served as a Principal of Summa Equity AB since July 2019. Dr. Roelofs has also served as Industrial Advisor of Nordic Capital since 2014. Dr. Roelofs serves as chairman of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., One BioMed Pte Ltd., ScaleBio Ltd., and Boreal Genomics Inc. Dr. Roelofs also serves as a member of the board of directors of multiple privately-held companies, including HyTest Ltd., The Binding Site Group Ltd., InSilixa, Inc., and LGC Group. He also serves as an advisory board member of 908 Devices Inc. Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc., and Chief Operating Officer of Stratagene Inc. Dr. Roelofs received his Bachelor of Science in chemistry, biology, and German from Simpson College, his Master of Science in organic chemistry from Iowa State University, and his doctorate in organic chemistry from University of Nevada, Reno.
Gustavo Salem

Gustavo Salem自2020年12月起担任我们的董事会成员。Salem先生自2020年3月起担任Summa Equity AB的负责人。自2019年1月成立以来,塞勒姆先生一直担任Eureka Life Science LLC的联合创始人兼管理合伙人,该公司为生命科学和诊断市场上的创新公司提供业务战略和商业化支持。2016年10月至2019年1月,塞勒姆先生担任IDEX健康与科学总裁兼IDEX Corporation集团总裁。从2015年3月至2016年10月,Salem先生担任IDEX Health and Science,LLC的总裁,从2014年4月至2015年2月,担任Siscapa Assay Technologies,Inc.的总裁兼首席执行官。Salem先生自2019年8月起担任Lideran&231;A Group Inc.的董事会主席,并担任多家私人控股公司的董事会成员,包括Siscapa Assay Technologies,Inc.,IROA Technologies LLC和Sengenics Corporation Pte Ltd.。Salem先生在加州大学伯克利分校(University of California,Berkeley)获得生理心理学文学学士学位,是加州大学欧文分校(University of California,Irvine)的心理生物学理学硕士候选人。


Gustavo Salem has served as a member of our Board of Directors since December 2020. Mr. Salem has served as a Principal of Summa Equity AB since March 2020. Since its inception in January 2019 Mr. Salem has served as the co-founder and managing partner of Eureka Life Science LLC, which provides business strategy and commercialization support for innovative companies across the life sciences and diagnostics markets. From October 2016 through January 2019 Mr. Salem served as President of IDEX Health and Science and Group President of IDEX Corporation. From March 2015 until October 2016 Mr. Salem served as President of IDEX Health and Science, LLC and, from April 2014 until February 2015 served as President and Chief Executive Officer of SISCAPA Assay Technologies, Inc. Mr. Salem has served as the chairman of the board of directors of Liderança Group Inc. since August 2019 and also serves as a member of the board of directors of multiple privately-held companies, including SISCAPA Assay Technologies, Inc., IROA Technologies LLC and Sengenics Corporation Pte Ltd. Mr. Salem received his Bachelor of Arts in physiological psychology from University of California, Berkeley and was a Master of Science candidate in psychobiology at University of California, Irvine.
Gustavo Salem自2020年12月起担任我们的董事会成员。Salem先生自2020年3月起担任Summa Equity AB的负责人。自2019年1月成立以来,塞勒姆先生一直担任Eureka Life Science LLC的联合创始人兼管理合伙人,该公司为生命科学和诊断市场上的创新公司提供业务战略和商业化支持。2016年10月至2019年1月,塞勒姆先生担任IDEX健康与科学总裁兼IDEX Corporation集团总裁。从2015年3月至2016年10月,Salem先生担任IDEX Health and Science,LLC的总裁,从2014年4月至2015年2月,担任Siscapa Assay Technologies,Inc.的总裁兼首席执行官。Salem先生自2019年8月起担任Lideran&231;A Group Inc.的董事会主席,并担任多家私人控股公司的董事会成员,包括Siscapa Assay Technologies,Inc.,IROA Technologies LLC和Sengenics Corporation Pte Ltd.。Salem先生在加州大学伯克利分校(University of California,Berkeley)获得生理心理学文学学士学位,是加州大学欧文分校(University of California,Irvine)的心理生物学理学硕士候选人。
Gustavo Salem has served as a member of our Board of Directors since December 2020. Mr. Salem has served as a Principal of Summa Equity AB since March 2020. Since its inception in January 2019 Mr. Salem has served as the co-founder and managing partner of Eureka Life Science LLC, which provides business strategy and commercialization support for innovative companies across the life sciences and diagnostics markets. From October 2016 through January 2019 Mr. Salem served as President of IDEX Health and Science and Group President of IDEX Corporation. From March 2015 until October 2016 Mr. Salem served as President of IDEX Health and Science, LLC and, from April 2014 until February 2015 served as President and Chief Executive Officer of SISCAPA Assay Technologies, Inc. Mr. Salem has served as the chairman of the board of directors of Liderança Group Inc. since August 2019 and also serves as a member of the board of directors of multiple privately-held companies, including SISCAPA Assay Technologies, Inc., IROA Technologies LLC and Sengenics Corporation Pte Ltd. Mr. Salem received his Bachelor of Arts in physiological psychology from University of California, Berkeley and was a Master of Science candidate in psychobiology at University of California, Irvine.
Tommi Unkuri

Tommi Unkuri自2019年3月起担任我们的董事会成员。Unkuri先生自2016年5月起担任Summa Equity AB的合伙人。从2015年11月至2016年5月,Unkuri先生担任Fidelio Capital AB的合伙人,从2007年4月至2015年12月,Unkuri先生在Nordic Capital AB的投资部门工作。Unkuri先生目前担任多家私人控股公司的董事会成员,包括Sengenics Corporation Pte Ltd.,Logex Group和Hytest Ltd.。Unkuri先生在斯德哥尔摩经济学院(Stockholm School of Economics)获得理学硕士学位。


Tommi Unkuri has served as a member of our Board of Directors since March 2019. Mr. Unkuri has served as a Partner of Summa Equity AB since May 2016. From November 2015 until May 2016 Mr. Unkuri was a Partner at Fidelio Capital AB, and from April 2007 until December 2015 Mr. Unkuri worked with investments at Nordic Capital AB. Mr. Unkuri currently serves as a member of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., LOGEX Group and HyTest Ltd. Mr. Unkuri received his Master of Science from the Stockholm School of Economics.
Tommi Unkuri自2019年3月起担任我们的董事会成员。Unkuri先生自2016年5月起担任Summa Equity AB的合伙人。从2015年11月至2016年5月,Unkuri先生担任Fidelio Capital AB的合伙人,从2007年4月至2015年12月,Unkuri先生在Nordic Capital AB的投资部门工作。Unkuri先生目前担任多家私人控股公司的董事会成员,包括Sengenics Corporation Pte Ltd.,Logex Group和Hytest Ltd.。Unkuri先生在斯德哥尔摩经济学院(Stockholm School of Economics)获得理学硕士学位。
Tommi Unkuri has served as a member of our Board of Directors since March 2019. Mr. Unkuri has served as a Partner of Summa Equity AB since May 2016. From November 2015 until May 2016 Mr. Unkuri was a Partner at Fidelio Capital AB, and from April 2007 until December 2015 Mr. Unkuri worked with investments at Nordic Capital AB. Mr. Unkuri currently serves as a member of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., LOGEX Group and HyTest Ltd. Mr. Unkuri received his Master of Science from the Stockholm School of Economics.
Jon Heimer

Jon Heimer自2014年起担任Olink Proteomics AB的董事长,自2016年1月起担任Olink Proteomics AB的首席执行官,自2020年12月起担任董事会成员。在加入我们之前,从2011年4月到2015年12月,Heimer先生担任NextTobe AB的合伙人,这是一家专注于瑞典生物技术行业的家族办公室/投资公司。Heimer先生曾担任Q-Linea AB的董事会主席,以及多家私人持有的生物技术公司的董事会主席,包括Bioimics AB和Lumina Adhesives AB。Heimer先生是一位连续创业者,是1990年代Q-Med成功起步的关键人物之一,并在生物技术领域的各种投资和成长型公司中度过了他职业生涯的很大一部分时间。


Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015 Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.
Jon Heimer自2014年起担任Olink Proteomics AB的董事长,自2016年1月起担任Olink Proteomics AB的首席执行官,自2020年12月起担任董事会成员。在加入我们之前,从2011年4月到2015年12月,Heimer先生担任NextTobe AB的合伙人,这是一家专注于瑞典生物技术行业的家族办公室/投资公司。Heimer先生曾担任Q-Linea AB的董事会主席,以及多家私人持有的生物技术公司的董事会主席,包括Bioimics AB和Lumina Adhesives AB。Heimer先生是一位连续创业者,是1990年代Q-Med成功起步的关键人物之一,并在生物技术领域的各种投资和成长型公司中度过了他职业生涯的很大一部分时间。
Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015 Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.
Solange Glaize

Solange Glaize,自2012年3月开始,她担任Olink Holding Ab (Publ)的副总裁兼公司主管兼首席会计官。2012年3月至2012年3月,她担任负责财务及业务发展的副总裁以及集团财务总监,负责生命科学组。2009年9月至2011年6月,她担任集团财务总监,负责生命科学组。2005年5月至2009年11月,她担任生命科学解决方案部财务高级总监。她曾在安捷伦担任很多职位,包括:负责全球订单履行的财务总监、销售财务及行政总监、半导体产品集团负责欧洲的金融服务董事及董事总经理。在加入安捷伦之前,她在Hewlett-Packard公司担任很多财务职位。


Solange Glaize has served as a member of Olink Holding Ab (Publ) Board of Directors since January 2021. Ms. Glaize is the Managing Principal of Scale2Growth, which she founded in November 2017. From June 2015 to October 2017 Ms. Glaize served as the Chief Financial Officer of Twist Bioscience Corporation. Prior to Twist, Ms. Glaize served as Life Sciences Group Chief Financial Officer and then as Chief Accounting Officer at Agilent Technologies Inc. Ms. Glaize has previously served on the Board of Directors of the European IRG Foundation for Agilent Technologies and Friends of HEC Inc. Ms. Glaize received her Master of Science in Management from the HEC Ecole des Hautes Etudes Commerciales School of Management in Paris, France.
Solange Glaize,自2012年3月开始,她担任Olink Holding Ab (Publ)的副总裁兼公司主管兼首席会计官。2012年3月至2012年3月,她担任负责财务及业务发展的副总裁以及集团财务总监,负责生命科学组。2009年9月至2011年6月,她担任集团财务总监,负责生命科学组。2005年5月至2009年11月,她担任生命科学解决方案部财务高级总监。她曾在安捷伦担任很多职位,包括:负责全球订单履行的财务总监、销售财务及行政总监、半导体产品集团负责欧洲的金融服务董事及董事总经理。在加入安捷伦之前,她在Hewlett-Packard公司担任很多财务职位。
Solange Glaize has served as a member of Olink Holding Ab (Publ) Board of Directors since January 2021. Ms. Glaize is the Managing Principal of Scale2Growth, which she founded in November 2017. From June 2015 to October 2017 Ms. Glaize served as the Chief Financial Officer of Twist Bioscience Corporation. Prior to Twist, Ms. Glaize served as Life Sciences Group Chief Financial Officer and then as Chief Accounting Officer at Agilent Technologies Inc. Ms. Glaize has previously served on the Board of Directors of the European IRG Foundation for Agilent Technologies and Friends of HEC Inc. Ms. Glaize received her Master of Science in Management from the HEC Ecole des Hautes Etudes Commerciales School of Management in Paris, France.
Tina S. Nova

Tina S. Nova博士自2014年4月成为董事会的成员,同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.,这是一家医药实验室诊断公司,她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix,担任Genoptix的首席执行官,同时是Genoptix董事会成员。此前,Nova先生联合创建了Nanogen, Inc.,Nanogen, Inc.是一家分子诊断测试的提供商,她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前,Nova博士担任Selective Genetics的首席运营官,这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.(Eli Lilly & Company的前子公司)担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校(niversity of California, Irvine)获得生物科学学士学位。从加州大学里弗赛德分校(University of California, Riverside)获得生物化学博士学位。


Tina S. Nova has served as a member of Olink Holding Ab (Publ) Board of Directors since January 2021. Dr. Nova has served as President and Chief Executive Officer of Decipher BioSciences, Inc. since August 2018. From September 2015 to July 2019 Dr. Nova served as President and Chief Executive Officer of Molecular Stethoscope, Inc. From July 2014 to August 2015 Dr. Nova served as Senior Vice President and General Manager of Illumina, Inc. Dr. Nova has served on the board of directors, and as the chairman of the board of directors, of Arena Pharmaceuticals, Inc. and on the board of directors of Veracyte, Inc. Dr. Nova received her Bachelor of Science in biological sciences from the University of California, Irvine and her PhD in biochemistry from the University of California, Riverside.
Tina S. Nova博士自2014年4月成为董事会的成员,同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.,这是一家医药实验室诊断公司,她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix,担任Genoptix的首席执行官,同时是Genoptix董事会成员。此前,Nova先生联合创建了Nanogen, Inc.,Nanogen, Inc.是一家分子诊断测试的提供商,她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前,Nova博士担任Selective Genetics的首席运营官,这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.(Eli Lilly & Company的前子公司)担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校(niversity of California, Irvine)获得生物科学学士学位。从加州大学里弗赛德分校(University of California, Riverside)获得生物化学博士学位。
Tina S. Nova has served as a member of Olink Holding Ab (Publ) Board of Directors since January 2021. Dr. Nova has served as President and Chief Executive Officer of Decipher BioSciences, Inc. since August 2018. From September 2015 to July 2019 Dr. Nova served as President and Chief Executive Officer of Molecular Stethoscope, Inc. From July 2014 to August 2015 Dr. Nova served as Senior Vice President and General Manager of Illumina, Inc. Dr. Nova has served on the board of directors, and as the chairman of the board of directors, of Arena Pharmaceuticals, Inc. and on the board of directors of Veracyte, Inc. Dr. Nova received her Bachelor of Science in biological sciences from the University of California, Irvine and her PhD in biochemistry from the University of California, Riverside.

高管简历

中英对照 |  中文 |  英文
Jon Heimer

Jon Heimer自2014年起担任Olink Proteomics AB的董事长,自2016年1月起担任Olink Proteomics AB的首席执行官,自2020年12月起担任董事会成员。在加入我们之前,从2011年4月到2015年12月,Heimer先生担任NextTobe AB的合伙人,这是一家专注于瑞典生物技术行业的家族办公室/投资公司。Heimer先生曾担任Q-Linea AB的董事会主席,以及多家私人持有的生物技术公司的董事会主席,包括Bioimics AB和Lumina Adhesives AB。Heimer先生是一位连续创业者,是1990年代Q-Med成功起步的关键人物之一,并在生物技术领域的各种投资和成长型公司中度过了他职业生涯的很大一部分时间。


Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015 Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.
Jon Heimer自2014年起担任Olink Proteomics AB的董事长,自2016年1月起担任Olink Proteomics AB的首席执行官,自2020年12月起担任董事会成员。在加入我们之前,从2011年4月到2015年12月,Heimer先生担任NextTobe AB的合伙人,这是一家专注于瑞典生物技术行业的家族办公室/投资公司。Heimer先生曾担任Q-Linea AB的董事会主席,以及多家私人持有的生物技术公司的董事会主席,包括Bioimics AB和Lumina Adhesives AB。Heimer先生是一位连续创业者,是1990年代Q-Med成功起步的关键人物之一,并在生物技术领域的各种投资和成长型公司中度过了他职业生涯的很大一部分时间。
Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. Prior to joining us, from April 2011 until December 2015 Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.
Oskar Hjelm

Oskar Hjelm自2020年3月起担任我们的首席财务官。在加入我们之前,Hjelm先生于2017年9月至2020年2月在Alvarez&Marsal Sweden AB的交易咨询组工作,为欧洲和北欧私募股权基金提供支持。从2016年8月至2017年8月,Hjelm先生担任毕马威会计事务所(KPMG AB)的董事。从2016年1月至2016年8月,Hjelm先生担任Nordic Capital的投资总监。从2008年7月到2015年12月,Hjelm先生在毕马威会计师事务所(KPMG AB)和毕马威会计师事务所(KPMG LLP)担任过各种职务。Hjelm先生在林克大学(Link&246;Pings University)获得商业与经济学理学硕士学位。


Oskar Hjelm has served as our Chief Financial Officer since March 2020. Prior to joining us, from September 2017 until February 2020 Mr. Hjelm worked at Alvarez & Marsal Sweden AB within their Transaction Advisory Group providing support to European and Nordic private equity funds. From August 2016 until August 2017 Mr. Hjelm was a director at KPMG AB. From January 2016 until August 2016 Mr. Hjelm was an investment controller at Nordic Capital. From July 2008 until December 2015 Mr. Hjelm held various roles at KPMG AB and KPMG LLP United Kingdom. Mr. Hjelm received his Master of Science in business and economics from Linköpings University.
Oskar Hjelm自2020年3月起担任我们的首席财务官。在加入我们之前,Hjelm先生于2017年9月至2020年2月在Alvarez&Marsal Sweden AB的交易咨询组工作,为欧洲和北欧私募股权基金提供支持。从2016年8月至2017年8月,Hjelm先生担任毕马威会计事务所(KPMG AB)的董事。从2016年1月至2016年8月,Hjelm先生担任Nordic Capital的投资总监。从2008年7月到2015年12月,Hjelm先生在毕马威会计师事务所(KPMG AB)和毕马威会计师事务所(KPMG LLP)担任过各种职务。Hjelm先生在林克大学(Link&246;Pings University)获得商业与经济学理学硕士学位。
Oskar Hjelm has served as our Chief Financial Officer since March 2020. Prior to joining us, from September 2017 until February 2020 Mr. Hjelm worked at Alvarez & Marsal Sweden AB within their Transaction Advisory Group providing support to European and Nordic private equity funds. From August 2016 until August 2017 Mr. Hjelm was a director at KPMG AB. From January 2016 until August 2016 Mr. Hjelm was an investment controller at Nordic Capital. From July 2008 until December 2015 Mr. Hjelm held various roles at KPMG AB and KPMG LLP United Kingdom. Mr. Hjelm received his Master of Science in business and economics from Linköpings University.
Rickard El Tarzi

Rickard El Tarzi自2020年2月起担任我们的首席战略官,并于2019年3月至2020年2月担任董事会成员。在加入我们之前,从2017年1月至2020年2月,El Tarzi先生担任Summa Equity AB投资团队的投资总监。从2012年4月到2016年4月,El Tarzi先生在麦肯锡公司(McKinsey&Company)任职,为欧洲和美国的投资者和企业客户提供战略与并购方面的建议。El Tarzi先生在哥德堡大学商学院(University of Gothenburg School of Business,Economics,and Law)获得物流与运输管理理学学士学位和管理理学硕士学位。


Rickard El Tarzi has served as our Chief Strategy Officer since February 2020 and served as a member of our Board of Directors from March 2019 to February 2020. Prior to joining us, from January 2017 until February 2020 Mr. El Tarzi served as an investment director on the investment team of Summa Equity AB. From April 2012 until April 2016 Mr. El Tarzi worked at McKinsey & Company advising investor and corporate clients across Europe and the United States on strategy and mergers and acquisitions. Mr. El Tarzi received his Bachelor of Science in logistics and transport management and his Master of Science in management from University of Gothenburg School of Business, Economics, and Law.
Rickard El Tarzi自2020年2月起担任我们的首席战略官,并于2019年3月至2020年2月担任董事会成员。在加入我们之前,从2017年1月至2020年2月,El Tarzi先生担任Summa Equity AB投资团队的投资总监。从2012年4月到2016年4月,El Tarzi先生在麦肯锡公司(McKinsey&Company)任职,为欧洲和美国的投资者和企业客户提供战略与并购方面的建议。El Tarzi先生在哥德堡大学商学院(University of Gothenburg School of Business,Economics,and Law)获得物流与运输管理理学学士学位和管理理学硕士学位。
Rickard El Tarzi has served as our Chief Strategy Officer since February 2020 and served as a member of our Board of Directors from March 2019 to February 2020. Prior to joining us, from January 2017 until February 2020 Mr. El Tarzi served as an investment director on the investment team of Summa Equity AB. From April 2012 until April 2016 Mr. El Tarzi worked at McKinsey & Company advising investor and corporate clients across Europe and the United States on strategy and mergers and acquisitions. Mr. El Tarzi received his Bachelor of Science in logistics and transport management and his Master of Science in management from University of Gothenburg School of Business, Economics, and Law.
Ida Grundberg

Ida Grundberg自2019年9月起担任我们的首席科学官。在加入我们之前,Grundberg博士于2011年9月至2019年9月在我们的子公司Olink Proteomics AB担任过各种职务,包括高级科学家,项目经理,业务开发经理,北美业务开发主管以及北美销售与市场营销Vice President。Grundberg博士在UME&229;University获得理学学士学位,在UME&229;University获得分子生物学理学硕士学位,在Uppsala University获得分子医学博士学位。


Ida Grundberg has served as our Chief Scientific Officer since September 2019. Prior to joining us, from September 2011 until September 2019 Dr. Grundberg served in various roles at our subsidiary, Olink Proteomics AB, including Senior Scientist, Project Manager, Business Development Manager, Head of Business Development for North America, and Vice President of Sales and Marketing for North America. Dr. Grundberg received her Bachelor of Science from Umeå University, her Master of Science in molecular biology from Umeå University, and her PhD in molecular medicine from Uppsala University.
Ida Grundberg自2019年9月起担任我们的首席科学官。在加入我们之前,Grundberg博士于2011年9月至2019年9月在我们的子公司Olink Proteomics AB担任过各种职务,包括高级科学家,项目经理,业务开发经理,北美业务开发主管以及北美销售与市场营销Vice President。Grundberg博士在UME&229;University获得理学学士学位,在UME&229;University获得分子生物学理学硕士学位,在Uppsala University获得分子医学博士学位。
Ida Grundberg has served as our Chief Scientific Officer since September 2019. Prior to joining us, from September 2011 until September 2019 Dr. Grundberg served in various roles at our subsidiary, Olink Proteomics AB, including Senior Scientist, Project Manager, Business Development Manager, Head of Business Development for North America, and Vice President of Sales and Marketing for North America. Dr. Grundberg received her Bachelor of Science from Umeå University, her Master of Science in molecular biology from Umeå University, and her PhD in molecular medicine from Uppsala University.
Carl Raimond

Carl Raimond自2020年10月起担任我们的首席商务官,之前从2020年8月开始担任我们的销售高级副总裁。在加入我们之前,Raimond先生于2015年1月至2020年2月在PerkinElmer担任过各种执行商业领导职务,包括Vice President和总经理美洲销售和服务和全球Vice President和总经理销售和服务的发现和分析解决方案部门。从2010年6月至2015年1月,雷蒙德先生担任安捷伦科技公司公司美洲生命科学销售和现场运营Vice President兼总经理。Raimond先生在奥斯威戈纽约州立大学学院(State University of New York College at Oswego)获得动物学文学学士学位,在布罗克波特纽约州立大学学院(State University of New York College at Brockport)获得生物学理学硕士学位。


Carl Raimond has served as our Chief Commercial Officer since October 2020 and previously served as our Senior Vice President of Sales beginning in August 2020. Prior to joining us, from January 2015 until February 2020 Mr. Raimond served in various executive commercial leadership roles at PerkinElmer, Inc. including Vice President and General Manager of Americas Sales and Service and Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. From June 2010 until January 2015 Mr. Raimond served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies, Inc. Mr. Raimond received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport.
Carl Raimond自2020年10月起担任我们的首席商务官,之前从2020年8月开始担任我们的销售高级副总裁。在加入我们之前,Raimond先生于2015年1月至2020年2月在PerkinElmer担任过各种执行商业领导职务,包括Vice President和总经理美洲销售和服务和全球Vice President和总经理销售和服务的发现和分析解决方案部门。从2010年6月至2015年1月,雷蒙德先生担任安捷伦科技公司公司美洲生命科学销售和现场运营Vice President兼总经理。Raimond先生在奥斯威戈纽约州立大学学院(State University of New York College at Oswego)获得动物学文学学士学位,在布罗克波特纽约州立大学学院(State University of New York College at Brockport)获得生物学理学硕士学位。
Carl Raimond has served as our Chief Commercial Officer since October 2020 and previously served as our Senior Vice President of Sales beginning in August 2020. Prior to joining us, from January 2015 until February 2020 Mr. Raimond served in various executive commercial leadership roles at PerkinElmer, Inc. including Vice President and General Manager of Americas Sales and Service and Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. From June 2010 until January 2015 Mr. Raimond served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies, Inc. Mr. Raimond received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport.
Fredrik Netzel

Fredrik Netzel自2019年9月起担任我们的首席运营官。在加入我们之前,Netzel先生于2019年4月至2019年9月担任Advantice Health,LLC.的高级运营总监。从2011年1月至2019年3月,Netzel先生担任Moberg Pharma AB(一家专注于OTC产品的制药公司)的高级运营总监,从2000年1月至2010年12月,Netzel先生担任Q-Med AB(一家医疗设备公司)的制造总监。Netzel先生曾在国际上工作,管理美国、加拿大和欧盟的CMO/3PL关系。此外,他曾为生命科学行业内的几家成长型公司开发运营。


Fredrik Netzel has served as our Chief Operating Officer since September 2019. Prior to joining us, from April 2019 until September 2019 Mr. Netzel served as Senior Director of Operations at Advantice Health, LLC. From January 2011 until March 2019 Mr. Netzel served as Senior Director of Operations at Moberg Pharma AB, a pharmaceutical company focused on OTC products and from January 2000 until December 2010 Mr. Netzel served as Director Manufacturing at Q-Med AB, a medical device company. Mr. Netzel has worked internationally, managing CMO/3PL relationships in the U.S., Canada, and EU. In addition, he has developed operations for several growth companies within the life sciences industry.
Fredrik Netzel自2019年9月起担任我们的首席运营官。在加入我们之前,Netzel先生于2019年4月至2019年9月担任Advantice Health,LLC.的高级运营总监。从2011年1月至2019年3月,Netzel先生担任Moberg Pharma AB(一家专注于OTC产品的制药公司)的高级运营总监,从2000年1月至2010年12月,Netzel先生担任Q-Med AB(一家医疗设备公司)的制造总监。Netzel先生曾在国际上工作,管理美国、加拿大和欧盟的CMO/3PL关系。此外,他曾为生命科学行业内的几家成长型公司开发运营。
Fredrik Netzel has served as our Chief Operating Officer since September 2019. Prior to joining us, from April 2019 until September 2019 Mr. Netzel served as Senior Director of Operations at Advantice Health, LLC. From January 2011 until March 2019 Mr. Netzel served as Senior Director of Operations at Moberg Pharma AB, a pharmaceutical company focused on OTC products and from January 2000 until December 2010 Mr. Netzel served as Director Manufacturing at Q-Med AB, a medical device company. Mr. Netzel has worked internationally, managing CMO/3PL relationships in the U.S., Canada, and EU. In addition, he has developed operations for several growth companies within the life sciences industry.
Linda Ramirez Eaves

Linda Ramirez Eaves自2019年2月起担任我们的总法律顾问。在加入我们之前,从2018年12月至2019年2月,Ramirez-Eaves女士担任希捷科技的高级公司法律顾问,从2015年9月至2018年12月,Ramirez-Eaves女士担任Somalogic,Inc.的高级法律顾问。从2014年12月到2015年9月,Ramirez-Eaves女士担任Ciber Global,LLC的高级法律顾问。Ramirez-Eaves女士在科罗拉多大学博尔德分校(University of Colorado at Boulder)获得新闻与大众传播理学学士学位,并在科罗拉多大学博尔德法学院(University of Colorado at Boulder School of Law)获得法学博士学位。Ramirez-Eaves女士自2018年以来一直是欧洲认证的信息隐私专业人士。


Linda Ramirez Eaves has served as our General Counsel since February 2019. Prior to joining us, from December 2018 to February 2019 Ms. Ramirez-Eaves served as Senior Corporate Counsel for Seagate Technologies, and from September 2015 until December 2018 Ms. Ramirez-Eaves served as Senior Counsel of SomaLogic, Inc. From December 2014 until September 2015 Ms. Ramirez-Eaves served as Senior Legal Counsel at Ciber Global, LLC. Ms. Ramirez-Eaves received her Bachelor of Science in Journalism and Mass Communications from the University of Colorado at Boulder, and her Juris Doctorate from the University of Colorado at Boulder School of Law. Ms. Ramirez-Eaves has been a Certified Information Privacy Professional/Europe since 2018.
Linda Ramirez Eaves自2019年2月起担任我们的总法律顾问。在加入我们之前,从2018年12月至2019年2月,Ramirez-Eaves女士担任希捷科技的高级公司法律顾问,从2015年9月至2018年12月,Ramirez-Eaves女士担任Somalogic,Inc.的高级法律顾问。从2014年12月到2015年9月,Ramirez-Eaves女士担任Ciber Global,LLC的高级法律顾问。Ramirez-Eaves女士在科罗拉多大学博尔德分校(University of Colorado at Boulder)获得新闻与大众传播理学学士学位,并在科罗拉多大学博尔德法学院(University of Colorado at Boulder School of Law)获得法学博士学位。Ramirez-Eaves女士自2018年以来一直是欧洲认证的信息隐私专业人士。
Linda Ramirez Eaves has served as our General Counsel since February 2019. Prior to joining us, from December 2018 to February 2019 Ms. Ramirez-Eaves served as Senior Corporate Counsel for Seagate Technologies, and from September 2015 until December 2018 Ms. Ramirez-Eaves served as Senior Counsel of SomaLogic, Inc. From December 2014 until September 2015 Ms. Ramirez-Eaves served as Senior Legal Counsel at Ciber Global, LLC. Ms. Ramirez-Eaves received her Bachelor of Science in Journalism and Mass Communications from the University of Colorado at Boulder, and her Juris Doctorate from the University of Colorado at Boulder School of Law. Ms. Ramirez-Eaves has been a Certified Information Privacy Professional/Europe since 2018.